Drugs / GRC 8200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00836940 | Jun 2008 → May 2009 | type 2 diabetes mellitus | Glenmark Pharmaceuticals Europe Ltd. (R&D) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRC 8200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00836940 ↗ |
| Action | Inhibit | “a New Oral DPP -IV Inhibitor” NCT00836940 ↗ |
| Route | Oral | “New Oral DPP -IV Inhibitor” NCT00836940 ↗ |